Scroll to top

CLINUVEL’s SCENESSE® launched in Europe

20 June 2016

First commercial delivery, SCENESSE® approved as standard of care in the Netherlands.

CLINUVEL Pharmaceuticals Limited (ASX: CUV; XETRA-DAX: UR9; ADR: CLVLY) today announced that its drug SCENESSE® (afamelanotide 16mg) has been launched in Europe, with the first commercial delivery of the product under European marketing authorisation. Patients with the rare genetic disorder erythropoietic protoporphyria (EPP) in the Netherlands will be treated with SCENESSE® starting from this week. First treatments in Austria and Germany are expected in July.

Download PDF for more

We use cookies to give you the best experience.